6 Articles found
Idience Co., Ltd Articles
-
First-in-Human Dose Finding Study of Venadaparib (IDX-1197), a Potent and Selective PARP inhibitor, in Patients with Advanced Solid Tumors
Poly ADP-ribose polymerase (PARP) is an enzyme that is central to the repair of DNA replication errors known as single-strand breaks. PARP inhibitors are currently approved (or ovary, breast, pancreatic and prostate cancers which harbor BRCA1/2 ...
-
Phase lb study of venadaparib, a potent and selective PARP inhibitor, in homologous recombination repair (HRR) mutated breast cancer
Poly ADP-ribose polymerase (PARP) is an enzyme that is central to the repair of DNA replication errors and are currently approved for ovary, breast, pancreas and prostate cancers. VASTUS study (NCT04174716)1` is a basket trial investigating the ...
-
Idience: developing selective and potent PARP inhibitor IDX-1197 for solid tumors
The first wave of PARP inhibitors has improved outcomes in people with a variety of solid tumors. However, Idience has identified opportunities to improve the efficacy of existing drugs and overcome resistance. The company plans to target ...
-
Ildong’s subsidiary secures 1st anticancer drug pipeline
Idience, a subsidiary of Ildong Pharmaceutical, has acquired IDX-1197, an immunotherapy drug, as its first pipeline. The introduction of the new pipeline came four months after Ildong Pharmaceutical established Idience as a no research and ...
-
Abstract 4842: A comparative preclinical study of PARP inhibitors demonstrates superb properties for IDX-1197
Abstract Background PARP inhibitors have demonstrated clinically meaningful increase in progression-free survival as a single agent in women with recurrent ovarian cancer following a response to platinum-based chemotherapy. We aimed to develop a ...
-
Abstract A106: Development of IDX-1197, a novel, selective, and highly potent PARP inhibitor
Abstract Background: PARP inhibitors have demonstrated clinically meaningful increase in progression-free survival as a single agent in women with recurrent ovarian cancer following a response to platinum-based chemotherapy. However, there still ...